Prices for Drugs: Is Public Regulation Possible?
This issue has long been discussed in the State Duma. But now that the Ministry of Healthcare is planning to switch to another drug insurance system and include it into the Compulsory Health Insurance program suggesting reimbursement (partial or full) of the drug cost to the patients, the subject has become more topical.
Tamara Frolova, a member of the State Duma Committee for healthcare considers prices for drugs from the vital and essential drug list and for medical devices in clinical practice. Her opinion is published in her interview to Parlamentskaya Gazeta – a weekly bulletin of the Russian Federation Council.